Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenothiazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 0.94 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.94 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.94 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.94 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.94 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.94 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.94 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.94 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.94 |
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.94 |
| ▸ | MAPT | P10636 | 7/20 | 0.94 |
| ▸ | MEN1 | O00255 | 3/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.94 |
| ▸ | SNCA | P37840 | 3/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | POLB | P06746 | 1/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenothiazine SCHEMBL31210230 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL27892294 | 1.00 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL11685385 | 0.97 | NOX1 (0.90) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL29352248 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL2504207 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL6315328 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL9114 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL29349533 | 0.97 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL23683396 | 0.94 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL21635186 | 0.94 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006117760-A1 | ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-7008934-B2 | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins | BAXTER INTERNATIONAL INC. (US) | 2006-03-07 | — | — | US | claimed |
| US-5952329-A | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors | THE GENERAL HOSPITAL CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| US-20250145605-A1 | CRYSTAL FORM AND SALT OF PHENOTHIAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU HENGHAO INNOVATIVE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| CN-115073625-B | Reduced and oxidized polysaccharides and methods of use thereof | 哈佛学院院长等 | 2024-01-16 | — | — | CN | disclosed |
| EP-4221714-A1 | ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE | Genus Lifesciences Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023143350-A1 | CRYSTAL FORM AND SALT OF PHENOTHIAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都恒昊创新科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-11680052-B2 | Method for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride or bromide | Mikrochem Spol. S R.o. (SK) | 2023-06-20 | — | — | US | disclosed |
| CN-115073625-A | Reduced and oxidized polysaccharides and methods of use thereof | 哈佛学院院长等 | 2022-09-20 | — | — | CN | disclosed |
| CN-114574147-A | Solvent-free polyurethane adhesive | 陈文娟 | 2022-06-03 | — | — | CN | disclosed |
| CN-108430458-B | Reduced and oxidized polysaccharides and methods of use thereof | 哈佛学院院长等 | 2022-05-10 | — | — | CN | disclosed |
| US-20110154510-A1 | AUTOMATED HIGH-CONTENT LIVE ANIMAL DRUG SCREENING USING C. ELEGANS | THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-06-23 | — | — | US | disclosed |
| US-20110086101-A1 | Dispersinb, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K-Based Antibiofilm Compositions and Uses Thereof | PIVOT FINANCIAL INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| EP-2283130-A1 | DISPERSINBtm, 5-FLUOROURACIL, DEOXYRIBONUCLEASE I AND PROTEINASE K-BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF | Kane Biotech Inc. (CA) | 2011-02-16 | — | — | EP | disclosed |
| US-20100204215-A1 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) | 2010-08-12 | — | — | US | disclosed |
| WO-2009121183-A1 | DISPERSINBTM, 5-FLUOROURACIL, DEOXYRIBONUCLEASE I AND PROTEINASE K-BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF | KANE BIOTECH INC. (CA) | 2009-10-08 | — | — | WO | disclosed |
| CN-101386606-A | 3-amino-7-dialkylamino substituted phenothiazine compounds and preparation method and application thereof | INST MATERIA MEDICA CAMS (CN) | 2009-03-18 | — | — | CN | disclosed |
| CN-1960986-A | Butyrylcholinesterase selective inhibitors | NEUROPHARMA S A U (ES) | 2007-05-09 | — | — | CN | disclosed |
| CN-1693879-A | Method and kit for investigating humotype semi-cystinol by enzyme biochemical reaction | ZHEJIANG YAKE PHARMACEUTICAL C (CN) | 2005-11-09 | — | — | CN | disclosed |
| US-5952329-A | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors | THE GENERAL HOSPITAL CORPORATION (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680052-B2 | Method for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride or bromide | MRPS7, B2M, UQCRB | GAA 4409/4885BCHE 2925/4885ACHE 3118/4885 |
| US-20250145605-A1 | CRYSTAL FORM AND SALT OF PHENOTHIAZINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC39A11, SLC7A11, SLC39A14 | GAA 2154/4885BCHE 3180/4885ACHE 4327/4885 |
| US-20100204215-A1 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | AOC1, DDT, DDC | GAA 1136/4885BCHE 2562/4885ACHE 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.